[go: up one dir, main page]

AR058193A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
AR058193A1
AR058193A1 ARP060105041A ARP060105041A AR058193A1 AR 058193 A1 AR058193 A1 AR 058193A1 AR P060105041 A ARP060105041 A AR P060105041A AR P060105041 A ARP060105041 A AR P060105041A AR 058193 A1 AR058193 A1 AR 058193A1
Authority
AR
Argentina
Prior art keywords
otic
pharmaceutically acceptable
administration
buprenorphine
animal
Prior art date
Application number
ARP060105041A
Other languages
English (en)
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37745944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058193(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of AR058193A1 publication Critical patent/AR058193A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se revela un método para proveer analgesia sistémica a gatos, perros y otros mamíferos pequenos mediante la administracion otica o transdérmica de opioides. También se revelan composiciones para utilizar en dicho método. Reivindicacion 1: Una composicion farmacéuticamente aceptable para la administracion otica a un animal que comprende buprenorfina, un sistema portador farmacéuticamente aceptable que comprende un solvente que consiste en una fase acuosa y en una fase orgánica, y al menos un agente mejorador de la penetracion. Reivindicacion 20: Uso de la composicion farmacéuticamente aceptable de la reivindicacion 1, caracterizado porque es para la manufactura de un medicamento util para introducir analgesia en un animal mediante la administracion por vía otica e buprenorfina.
ARP060105041A 2005-11-21 2006-11-16 Composiciones farmaceuticas AR058193A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73852405P 2005-11-21 2005-11-21

Publications (1)

Publication Number Publication Date
AR058193A1 true AR058193A1 (es) 2008-01-23

Family

ID=37745944

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105041A AR058193A1 (es) 2005-11-21 2006-11-16 Composiciones farmaceuticas

Country Status (17)

Country Link
US (2) US20070117828A1 (es)
EP (2) EP1954275A2 (es)
JP (2) JP2009516687A (es)
KR (1) KR20080071185A (es)
CN (1) CN101312730A (es)
AR (1) AR058193A1 (es)
AU (1) AU2006316607A1 (es)
BR (1) BRPI0618891A2 (es)
CA (2) CA2630072A1 (es)
EC (1) ECSP088461A (es)
NO (1) NO20082833L (es)
NZ (1) NZ568313A (es)
PE (1) PE20070643A1 (es)
RU (1) RU2008124805A (es)
TW (1) TW200738240A (es)
WO (2) WO2007061739A2 (es)
ZA (2) ZA200804305B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709410A2 (pt) * 2006-03-20 2011-07-12 Javelin Pharmaceuticals Inc composição farmacêutica e método para tratar um mamìfero necessitando de um agente analgésico, anti-inflamatório ou um antipirético
KR20140038575A (ko) * 2006-03-28 2014-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
GB2461681A (en) * 2008-04-17 2010-01-13 Pharmasol Ltd Buprenorphine liquid spray formulation with solvent and antioxidant
PE20081406A1 (es) * 2006-12-20 2008-10-17 Schering Plough Ltd Composiciones farmaceuticas de flunixina
MX2010004373A (es) * 2007-11-01 2010-05-05 Bausch & Lomb Materiales miscibles en agua no acuosos como vehiculos para suministro de farmacos.
CA2728727C (en) * 2008-06-24 2018-01-23 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
WO2010072398A2 (en) 2008-12-22 2010-07-01 Boehringer Ingelheim Limited Veterinary formulations
US20120277199A1 (en) * 2009-10-21 2012-11-01 Otonomy, Inc. Modulation of Gel Temperature of Poloxamer-Containing Formulations
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
CA2808628A1 (en) * 2010-08-17 2012-02-23 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
CA2808237C (en) * 2010-09-03 2019-08-06 Abbott Laboratories High dose buprenorphine compositions and use as analgesic
CA2804797C (en) * 2010-10-25 2014-12-23 University Of Manitoba Therapeutic compositions for diabetic symmetrical polyneuropathy and/or tactile allodynia
WO2013070656A1 (en) * 2011-11-07 2013-05-16 Navinta Llc Sustained release suspension preparation for dextromethorphan
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
WO2014160702A1 (en) * 2013-03-25 2014-10-02 Chs Pharma, Inc. Retinopathy treatment
EP2983668A4 (en) * 2013-04-08 2017-01-11 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
SG11201703632WA (en) 2014-11-07 2017-06-29 Indivior Uk Ltd Buprenorphine dosing regimens
CA3003293A1 (en) * 2015-10-27 2017-05-04 Insys Development Company, Inc. Liquid buprenorphine formulations
MY196269A (en) * 2016-09-13 2023-03-24 Alar Pharmaceuticals Inc Sustained-Release Buprenorphine Formulations
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
GB201716830D0 (en) * 2017-10-13 2017-11-29 Cambrex Charles City Inc New Process
BR112020007808A2 (pt) 2017-10-20 2020-10-20 Chiesi Farmaceutici S.P.A. formulações farmacêuticas que compreendem um agonista de receptor de opioide como ingrediente ativo, métodos de fabricação e usos terapêuticos destas
US11419866B2 (en) * 2018-01-22 2022-08-23 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
EP4408394A1 (en) * 2021-09-30 2024-08-07 Elanco Us Inc. Stable formulations of buprenorphine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8533582A (en) * 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US6384043B1 (en) * 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
PT889723E (pt) * 1996-03-25 2002-11-29 Lohmann Therapie Syst Lts Sistema terapeutico transdermico com pequena espressura da zona de aplicacao e elevada flexibilidade assim como processo de producao
US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
IT1302682B1 (it) * 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
AU5170400A (en) * 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
EP1272035A1 (en) * 2000-07-13 2003-01-08 Euro-Celtique, S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
US20040258740A1 (en) * 2003-04-10 2004-12-23 Nene Labs Transdermal delivery composition

Also Published As

Publication number Publication date
CA2630072A1 (en) 2007-05-31
ECSP088461A (es) 2008-06-30
US20070117828A1 (en) 2007-05-24
AU2006316607A1 (en) 2007-05-31
ZA200804355B (en) 2009-04-29
ZA200804305B (en) 2009-04-29
PE20070643A1 (es) 2007-08-10
WO2007061739A2 (en) 2007-05-31
CA2629560A1 (en) 2007-05-31
CN101312730A (zh) 2008-11-26
TW200738240A (en) 2007-10-16
WO2007061828A2 (en) 2007-05-31
WO2007061828A3 (en) 2007-07-19
NZ568313A (en) 2011-11-25
JP2009516687A (ja) 2009-04-23
WO2007061739A3 (en) 2007-07-12
JP2009516686A (ja) 2009-04-23
US20070116730A1 (en) 2007-05-24
EP1954275A2 (en) 2008-08-13
BRPI0618891A2 (pt) 2011-09-13
EP1951240A2 (en) 2008-08-06
RU2008124805A (ru) 2009-12-27
NO20082833L (no) 2008-07-29
KR20080071185A (ko) 2008-08-01

Similar Documents

Publication Publication Date Title
AR058193A1 (es) Composiciones farmaceuticas
CR6654A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
PE20081297A1 (es) Forma de dosificacion transdermica resistente a la manipulacion
BRPI0819235A2 (pt) Sistema de distribuição transdérmica para hormônios e esteróides
ECSP088670A (es) Sistema de administracion de plaguicidas
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
BRPI0921687A8 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
BRPI0510909A2 (pt) composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
BRPI0517091B8 (pt) composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
CL2010001642A1 (es) Composicion farmaceutica topica en gel que comprende a) 0,25 a 4,5% de un agente activo para el tratamiento de la queratosis actinica, b) un agente queratoliticamente activo, c) un formador de gel, d) un solvente organico, y menos de 5% en peso de agua; util para el tratamiento de la queratosis actinica.
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
AR067751A1 (es) Composicion veterinaria topica, proceso para la preparacion de una composicion y metodo para el tratamiento de infeccion endoparasitaria o infestacion en un animal homeotermico
CL2011000044A1 (es) Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria.
CL2009001080A1 (es) Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo.
WO2010019611A3 (en) Bridged polycyclic compound based compositions for topical and oral applications
MXPA04011990A (es) Composiciones farmaceuticas estabilizadas en la base de aceite de ricino polioxietilado y metodo para fabricar el mismo.
BR0312814A (pt) Levamisol / avermectinas ou similares em solvente de pirrolidona
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
AR064104A1 (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas
BRPI0413883A (pt) composição e método para a administração de um composto farmacologicamente ativo a um mamìfero
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada

Legal Events

Date Code Title Description
FA Abandonment or withdrawal